A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin.

Trial Profile

A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2015

At a glance

  • Drugs GSK 256073 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 18 Nov 2011 Additional location (Scotland) added as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top